Literature DB >> 18006445

Proteasome activation during cardiac hypertrophy by the chaperone H11 Kinase/Hsp22.

Nadia Hedhli1, Li Wang, Qian Wang, Eman Rashed, Yimin Tian, Xiangzhen Sui, Kiran Madura, Christophe Depre.   

Abstract

AIMS: The regulation of protein degradation by the proteasome during cardiac hypertrophy remains largely unknown. Also, the proteasome translocates to the nuclear periphery in response to cellular stress in yeast, which remains unexplored in mammals. The purpose of this study was to determine the quantitative and qualitative adaptation of the proteasome during stable cardiac hypertrophy. METHODS AND
RESULTS: We measured proteasome activity, expression and sub-cellular distribution in a model of chronic cardiac hypertrophy induced by the stress-response chaperone H11 Kinase/Hsp22 (Hsp22). Over-expression of Hsp22 in a transgenic (TG) mouse leads to a 30% increase in myocyte cross-sectional area compared to wild-type (WT) mice (P < 0.01). Characterization of the proteasome in hearts from TG mice vs. WT revealed an increased expression of both 19S and 20S subunits (P < 0.05), a doubling in 20S catalytic activity (P < 0.01), a redistribution of both subunits from the cytosol to the nuclear periphery, and a four-fold increase in nuclear-associated 20S catalytic activity (P < 0.001). The perinuclear proteasome co-localized and interacted with Hsp22. Inhibition of proteasome activity by epoxomicin reduced hypertrophy in TG by 50% (P < 0.05). Adeno-mediated over-expression of Hsp22 in isolated cardiac myocytes increased both cell growth and proteasome activity, and both were prevented upon inhibition of the proteasome. Similarly, stimulation of cardiac cell growth by pro-hypertrophic stimuli increased Hsp22 expression and proteasome activity, and proteasome inhibition in that setting prevented hypertrophy. Proteasome inhibitors also prevented the increase in rate of protein synthesis observed after over-expression of Hsp22 or upon addition of pro-hypertrophic stimuli.
CONCLUSIONS: Hsp22-mediated cardiac hypertrophy promotes an increased expression and activity, and a subcellular redistribution of the proteasome. Inhibition of the proteasome reverses cardiac hypertrophy upon Hsp22 over-expression or upon stimulation by pro-hypertrophic hormones, and also blocks the stimulation of protein synthesis in these conditions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006445     DOI: 10.1093/cvr/cvm054

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  25 in total

Review 1.  The ubiquitin-proteasome system and cardiovascular disease.

Authors:  Saul R Powell; Joerg Herrmann; Amir Lerman; Cam Patterson; Xuejun Wang
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 2.  Proteasome inhibitors and cardiac cell growth.

Authors:  Nadia Hedhli; Christophe Depre
Journal:  Cardiovasc Res       Date:  2009-07-03       Impact factor: 10.787

Review 3.  The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy.

Authors:  Lucie Carrier; Saskia Schlossarek; Monte S Willis; Thomas Eschenhagen
Journal:  Cardiovasc Res       Date:  2009-07-17       Impact factor: 10.787

4.  Catalytically Active Proteasomes Function Predominantly in the Cytosol.

Authors:  Francis Wang Dang; Li Chen; Kiran Madura
Journal:  J Biol Chem       Date:  2016-07-14       Impact factor: 5.157

5.  H11 kinase/heat shock protein 22 deletion impairs both nuclear and mitochondrial functions of STAT3 and accelerates the transition into heart failure on cardiac overload.

Authors:  Hongyu Qiu; Paulo Lizano; Lydie Laure; Xiangzhen Sui; Eman Rashed; Ji Yeon Park; Chull Hong; Shumin Gao; Eric Holle; Didier Morin; Sunil K Dhar; Thomas Wagner; Alain Berdeaux; Bin Tian; Stephen F Vatner; Christophe Depre
Journal:  Circulation       Date:  2011-07-11       Impact factor: 29.690

Review 6.  Role of ubiquitin-proteasome system (UPS) in left ventricular hypertrophy (LVH).

Authors:  Federico Cacciapuoti
Journal:  Am J Cardiovasc Dis       Date:  2014-01-15

Review 7.  Neuromuscular Diseases Due to Chaperone Mutations: A Review and Some New Results.

Authors:  Jaakko Sarparanta; Per Harald Jonson; Sabita Kawan; Bjarne Udd
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

8.  Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload.

Authors:  Nadia Hedhli; Paulo Lizano; Chull Hong; Luke F Fritzky; Sunil K Dhar; Huasheng Liu; Yimin Tian; Shumin Gao; Kiran Madura; Stephen F Vatner; Christophe Depre
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-08-01       Impact factor: 4.733

Review 9.  The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective.

Authors:  Huabo Su; Xuejun Wang
Journal:  Cardiovasc Res       Date:  2009-08-20       Impact factor: 10.787

10.  Meta-analysis of Transcriptomic Data Reveals Pathophysiological Modules Involved with Atrial Fibrillation.

Authors:  Rodrigo Haas Bueno; Mariana Recamonde-Mendoza
Journal:  Mol Diagn Ther       Date:  2020-10-23       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.